Parallel Advisors, LLC Ascendis Pharma A/S Transaction History
Parallel Advisors, LLC
- $4.87 Billion
- Q2 2025
A detailed history of Parallel Advisors, LLC transactions in Ascendis Pharma A/S stock. As of the latest transaction made, Parallel Advisors, LLC holds 156 shares of ASND stock, worth $32,485. This represents 0.0% of its overall portfolio holdings.
Number of Shares
156
Previous 156
-0.0%
Holding current value
$32,485
Previous $24,000
8.33%
% of portfolio
0.0%
Previous 0.0%
Shares
12 transactions
Others Institutions Holding ASND
# of Institutions
286Shares Held
60.7MCall Options Held
217KPut Options Held
73.3K-
Ra Capital Management, L.P. Boston, MA10.3MShares$2.14 Billion38.78% of portfolio
-
Westfield Capital Management CO LP Boston, MA5.48MShares$1.14 Billion4.42% of portfolio
-
Avoro Capital Advisors LLC New York, NY4.98MShares$1.04 Billion15.67% of portfolio
-
Janus Henderson Group PLC London, X04.43MShares$922 Million0.39% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI4.26MShares$886 Million1.14% of portfolio
About Ascendis Pharma A/S
- Ticker ASND
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,810,200
- Market Cap $11.6B
- Description
- Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...